Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Retained Earnings (2023 - 2025)

Telix Pharmaceuticals has reported Retained Earnings over the past 3 years, most recently at $101.6 million for Q4 2025.

  • Quarterly Retained Earnings fell 2.11% to $101.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.6 million through Dec 2025, down 2.11% year-over-year, with the annual reading at $101.6 million for FY2025, 166.42% up from the prior year.
  • Retained Earnings was $101.6 million for Q4 2025 at Telix Pharmaceuticals, down from $103.8 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $103.8 million in Q4 2024 and troughed at -$171.6 million in Q4 2023.
  • The 3-year median for Retained Earnings is $101.6 million (2025), against an average of $11.2 million.
  • Year-over-year, Retained Earnings skyrocketed 160.45% in 2024 and then decreased 2.11% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$171.6 million in 2023, then skyrocketed by 160.45% to $103.8 million in 2024, then dropped by 2.11% to $101.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Retained Earnings are $101.6 million (Q4 2025), $103.8 million (Q4 2024), and -$171.6 million (Q4 2023).